多替拉韦或拉替拉韦单药治疗在人源化小鼠中无法持久抑制HIV病毒血症
本研究在人源化小鼠(HSC-NSG)中比较多替拉韦与拉替拉韦单药治疗20周的疗效。拉替拉韦组4/4小鼠均未能维持病毒抑制,多替拉韦组5/5初始抑制但1只出现反弹。两种药物单药均不能持久抑制HIV,提示简化治疗策略可能需要双药联合。
要点
- 拉替拉韦单药治疗4/4小鼠均未能维持HIV病毒血症抑制。
- 多替拉韦单药治疗5/5小鼠初始抑制,但1只出现病毒血症反弹。
- 耐药病毒出现交叉耐药,提示单药简化治疗不可靠。
核心结论
- 拉替拉韦或多替拉韦单药治疗均不能持续维持HIV抑制,提示简化策略中可能需要双药治疗。
研究设计与样本
- 在人源化小鼠(HSC-NSG)中比较多替拉韦或拉替拉韦20周单药治疗,感染HIVBaL。
主要发现
- 未治疗对照小鼠病毒血症持续恒定,病毒对拉替拉韦(EC50<8 nM)和多替拉韦(EC50<1 nM)敏感。
- 拉替拉韦组4/4小鼠初始抑制后失败,病毒出现G140G/S和Q148H/K突变,对拉替拉韦(EC50>100 nM)和多替拉韦(EC50 8.8–13.3 nM)耐药。
- 多替拉韦组5/5小鼠初始抑制,1只反弹,病毒出现E138K、G140S、Q148H、N155H和S230R突变,对拉替拉韦(EC50>1000 nM)和多替拉韦(EC50 550 nM)高度耐药。
关键数值与推荐
- 拉替拉韦单药失败4/4,多替拉韦单药反弹1/5。
- 拉替拉韦失败病毒EC50:拉替拉韦>100 nM,多替拉韦8.8–13.3 nM。
- 多替拉韦反弹病毒EC50:拉替拉韦>1000 nM,多替拉韦550 nM。
临床怎么用
- 提示临床简化治疗策略中不应采用拉替拉韦或多替拉韦单药,需考虑双药联合方案。
局限性
- 研究为人源化小鼠模型,结果外推至人类需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the effectiveness of HIV integrase inhibitor monotherapy between raltegravir and dolutegravir as an approach to simplify therapy. METHODS: We evaluated and compared the efficacy of 20 week monotherapy with dolutegravir or raltegravir in humanized mice (HSC-NSG) infected with HIVBaL. Plasma HIV RNA was measured by quantitative RT-PCR (limit of detection of 150 copies/45 μL of plasma) and drug levels by LC-MS/MS. Escape viruses were genotyped and analysed for replication capacity and drug susceptibility in tissue culture. RESULTS: Drug-untreated control mice maintained constant viraemia throughout the study. Virus isolates from these mice were susceptible to both raltegravir (EC50 of <8 nM) and dolutegravir (EC50 of <1 nM). Mice treated with raltegravir or dolutegravir had plasma drug levels comparable to those in humans. Monotherapy with raltegravir initially suppressed HIV viraemia, but failed to maintain suppression in 4/4 mice. Viruses from raltegravir failing mice developed mutations G140G/S and Q148H/K, and were resistant to both raltegravir (EC50 values of >100 nM) and dolutegravir (EC50 values ranging from 8.8 to 13.3 nM). Monotherapy with dolutegravir suppressed viraemia in 5/5 of mice, but viraemia rebounded in one animal. The virus from this mouse had mutations E138K, G140S, Q148H, N155H and S230R, was highly resistant to both raltegravir (EC50 of >1000 nM) and dolutegravir (EC50 of 550 nM), and replicated to levels similar to those of control viruses in PBMCs. CONCLUSIONS: Monotherapy with either raltegravir or dolutegravir does not consistently maintain HIV suppression, suggesting that dual therapy may be required in simplification strategies.
引用
- Heredia A, Hassounah S, Medina-Moreno S, et al. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice. J Antimicrob Chemother. 2017. PMID: 28637235. doi:10.1093/jac/dkx195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。